DOCSLIB.ORG

The Vascular Mechanism of Action of Betahistine in the Inner Ear of the Guinea Pig

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Vascular Mechanism of Action of Betahistine in the Inner Ear of the Guinea Pig Eur Arch Otorhinolaryngol (1998) 255:119–123 © Springer-Verlag 1998 OTOLOGY E. Laurikainen · J. M. Miller · A. L. Nuttall · W. S. Quirk The vascular mechanism of action of betahistine in the inner ear of the guinea pig Received: 25 June 1997 / Accepted: 20 August 1997 Abstract The aim of this study was to investigate the 15% and occurred without a demonstrable change in cap- mechanism and site of action of betahistine dihydrochlo- illary diameters. In contrast, the diameter of the AICA in- ride in the inner ear of the guinea pig. Betahistine-evoked creased by 17–20%, indicating that betahistine-evoked in- increases in cochlear blood flow (CBF) have been pre- creases in CBF resulted primarily from vasodilatation of sumed to be due to the drug effect on the later wall capil- the AICA. We suggest that this effect may be mediated α lary bed or larger feeding vessels in the cochlea vascular via presynaptic H3 heteroreceptors and autonomic 2 re- system. As such, the mechanism of action could be due to ceptors. inhibition of H3 receptors. Betahistine may also have a di- rect effect on postsynaptic H1/H2 receptors and/or an ef- Key words Cochlear blood flow · Cochlear physiology · fect modulated by other autonomic receptors. Betahistine- Experimental vasodilatation · Betahistine treatment evoked CBF responses were assessed by laser Doppler α flowmetry in the presence of an H3 agonist ( N-methyl- histamine dihydrochloride), an H3 antagonist (thiopera- Introduction α mide), an H2 antagonist (cimetidine) or an 2 antagonist (idazoxan). The effects of betahistine on circulation in the Betahistine dihydrochloride is considered to be one of the anterior inferior cerebellar artery (AICA) and ipsilateral few vasoactive drugs that may have clinically beneficial stria vascularis (SV) were assessed using intravital mi- effects on such inner ear disorders as Menière’s disease croscopy (IVM). Findings showed that betahistine in- and tinnitus [7]. Although vasodilatation due to direct creased CBF and reduced systemic blood pressure (BP). stimulation of histaminergic H1 and H2 receptors has been In contrast, αN-methylhistamine dihydrochloride had no suggested to be a contributing factor to these effects, be- effect on baseline CBF or BP and did not influence be- tahistine is recognized to have only a weak effect on these tahistine-induced increases in CBF. Thioperamide re- receptors [8]. This study was carried out to further inves- versed the effects of betahistine on CBF, but had no effect tigate the possible mechanism and site of action of be- on baseline CBF or BP. Cimetidine had no marked effect tahistine on cochlear blood flow (CBF). on baseline CBF or betahistine-induced increases in CBF In a recent study, administration of betahistine either Idazoxan had no consistent effects on baseline CBF, but intravenously, or topically to the round window membrane, abolished the effect of betahistine on CBF. The mean in- or via the anterior inferior cerebellar artery (AICA) result- crease of red blood cell velocity in SV capillaries was ed in a specific effect on cochlear vessels [4]. This response was not affected by promethazine as an H1 histaminergic antagonist. In separate studies Arrang et al. [1] have de- scribed a novel H3 inhibitory presynaptic receptor. Action E. Laurikainen · J. M. Miller · A. L. Nuttall at this presynaptic receptor may have two effects: stimu- Kresge Hearing Research Institute, lation may cause an inhibition of histamine release to the Department of Otolaryngology, The University of Michigan, Ann Arbor, Michigan, USA postsynaptic site, or it may interact with other autonomic receptors to co-modulate vessel tone. Elsewhere, Ischi- E. Laurikainen (Y) kawa and Sperilakis [3] have reported an interaction be- Department of Otorhinolaryngology, Turku University Central Hospital, FIN-20520 Turku, Finland tween H3 and adrenergic receptors in the peripheral ner- vous system. W. S. Quirk As betahistine is recognized to be a strong H receptor The Cochlear Microcirculation Laboratory, 3 Department of Otorhinolaryngology, antagonist [2], it is possible that betahistine-evoked in- The Wayne State University, Detroit, Michigan, USA creases in CBF could be due to inhibition of H3 receptors, 120 thus causing an increase in histamine release and activa- sults were described in terms of the change (%∆CBF and %∆BP) tion of postsynaptic H and H receptors. In addition, be- from mean baseline levels, with baseline levels determined over a 1 2 period of at least 15 min before each experiment. tahistine may have a weak, but direct, effect on postsy- The effects of betahistine on circulation in the AICA and SV naptic H1 and H2 receptors and/or an effect modulated by were also observed in two guinea pigs using intravital microscopy other autonomic receptors. Indeed, in noradrenergic and (IVM). Each animal’s brainstem was exposed by removing the α esophagus and deeper straight neck muscles, after which the bony cholinergic systems, the inhibitory presynaptic 2 recep- tor has been shown to mediate electrically stimulated in- skull base was drilled off. Following penetration of the aura, the AICA was characteristically found to branch from the basilar creases in CBF [5]. However, it is possible that more than artery. For IVM observations of CBF, small windows were created one of these mechanisms of action may contribute to the with a 1-mm diamond drill in two or three sites over the membra- clinical benefits of betahistine. nous labyrinth. Systemically administered fluorescein was used to In our current study, potential mechanisms of betahis- enhance the contrast of microcirculation in the lateral wall capil- laries. tine as cochlear blood flow were assessed by determining the effects of a specific H3 antagonist, an H3 agonist, an α H2 antagonist and an 2 antagonist on betahistine-evoked Experimental procedures increases in CBF, using the guinea pig as an animal model. The site of action was also assessed by observing To verify a betahistine effect on CBF or study the interactions with other agents (see below), 12.4 mM betahistine was administered the vascular responses to betahistine in different regions systemically via a Sage 350 infusion pump into the left external of the cochlear vascular system, i.e., as the AICA and ip- jugular vein of six animals for 2 min at a rate of 0.3 ml/min. All silateral stria vascularis (SV). other drugs were infused into the right external jugular vein using a Sage model 354 infusion pump. Materials and methods Mode of action of betahistine Animals and preparation αN-Methylhistamine dihydrochloride (RBI, Natick, Mass., USA) Eighteen healthy adult male and female pigmented guinea pigs at a concentration of 12.5 mM was infused at a rate of 0.3 1 ml/min (weighing 310–400 g) were used to assess the mechanism of action for 2 min and was administered 10 min before any betahistine in- of betahistine. The study was consistent with the United States Na- fusion in order to assess the effect of a specific H3 receptor agonist tional Institute of Health (NIH) guidelines for the humane treat- on CBF and the effect of chemical stimulation of H3 receptors on ment of animals. The middle ear was examined in each animal betahistine-evoked increases in CBF in four animals. This proce- prior to study in order to exclude ears with incidental infections. dure was repeated twice in each animal following a 30-min recov- Animals were anesthetized with intraperitoneal pentobarbital ery period between infusions. (Nembutal) as 25 mg/ml or 0.6 ml/kg and in transmuscular fen- The same procedures were used to assess the effects of 6, 9, 12 tanyl with properidol (Innovar) as 0.4 mg/kg. Anestetics were pro- and 16 mM thioperamiede as a specific H3 receptor antagonist. vided by Sigma Chemicals (St. Louis, Mo., USA). An additional Drug was obtained from RBI and was infused for 2 min at a rate of half dose of Innovar was administered every 30 min in order to 0.3 ml/min. Cimetidine (Sigma Chemicals) was used as a specific maintain anesthesia. H2 antagonist and was infused in concentrations of 8, 16, 24 and Following tracheotomy, the carotid artery was cannulated for 32 mM at a rate of 0.3 ml/min for 2 min in five animals. Idazoxan α systemic blood pressure (BP) measurements while both external (Sigma Chemicals) served as 2-antagonist at concentrations of 3, jugular veins were used for drug administration. The head was 6, 9 and 12 mM and was infused at a rate of 0.3 ml/min for 2 min then fixed in a head restraint, and each animal being studied was in five animals. Although a 30-min recovery period was main- wrapped in a heating pad with a feedback system in order to main- tained between infusions, the result of each infusion represented a tain core temperature at 38 ± 1°C. cumulative effect of the drug employed. For laser Doppler flowmetry, TSI (TSI, Minnesota, USA) and Perimed PF3 (Perimed, Sweden) laser flowmeters were used as de- scribed in detail by Miller and Nuttall [6]. The tympanic bullae Site of action of betahistine were exposed surgically using a ventral approach, the mucosa over the second turn of the cochlea was gently removed and petroleum Observations of circulation in the AICA and SV during betahistine jelly was applied between the laser probe and the bone in order to infusions were made using IVM via small windows over the basal, improve optical coupling. Measurements were made over the sec- second and third turns of the cochlea. The effect of betahistine on ond turn by placing the probe perpendicular to the stria. CBF, BP AICA and SV diameter was also assessed under a surgical micro- and the conductivity of the cochlear vascular system (R CBF/BP) scope at × 450 (AICA) or × 1000 (SV) magnification (Fig.
Load more

Recommended publications
  • SYNTHESIS and STRUCTURE ACTIVITY STUDIES of NOVEL H3-RECEPTOR HISTAMINE ANTAGONISTS. a Thesis Presented in Partial Fulfilment Of
    1 SYNTHESIS AND STRUCTURE ACTIVITY STUDIES OF NOVEL H3-RECEPTOR HISTAMINE ANTAGONISTS. A thesis presented in partial fulfilment of the requirements for the Doctor of Philosophy Degree of the University of London SEYED KIUMARS HOSSEINI Department of Chemistry University College London September 1991 Attention is drawn to the fact that copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that the copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without prior consent of the author. Signature: Date..^*^^~ ProQuest Number: 10609847 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 10609847 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 2 Acknowledgements I would like to express my gratitude for the guidance and generous support of Prof. C. R. Ganellin and for the financial support of Bioproject in association with Centre Paul Broca de rinserm, Paris. Thanks to Prof.
    [Show full text]
  • In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs As Inverse H1 Receptor Agonists
    0022-3565/07/3221-172–179$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 322, No. 1 Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics 118869/3215703 JPET 322:172–179, 2007 Printed in U.S.A. In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists R. A. Bakker,1 M. W. Nicholas,2 T. T. Smith, E. S. Burstein, U. Hacksell, H. Timmerman, R. Leurs, M. R. Brann, and D. M. Weiner Department of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (R.A.B., H.T., R.L.); ACADIA Pharmaceuticals Inc., San Diego, California (R.A.B., M.W.N., T.T.S., E.S.B., U.H., M.R.B., D.M.W.); and Departments of Pharmacology (M.R.B.), Neurosciences (D.M.W.), and Psychiatry (D.M.W.), University of California, San Diego, California Received January 2, 2007; accepted March 30, 2007 Downloaded from ABSTRACT The human histamine H1 receptor (H1R) is a prototypical G on this screen, we have reported on the identification of 8R- protein-coupled receptor and an important, well characterized lisuride as a potent stereospecific partial H1R agonist (Mol target for the development of antagonists to treat allergic con- Pharmacol 65:538–549, 2004). In contrast, herein we report on jpet.aspetjournals.org ditions. Many neuropsychiatric drugs are also known to po- a large number of varied clinical and chemical classes of drugs tently antagonize this receptor, underlying aspects of their side that are active in the central nervous system that display potent effect profiles.
    [Show full text]
  • Monoamine Depletion in Psychiatric and Healthy Populations
    Molecular Psychiatry (2003) 8, 951–973 & 2003 Nature Publishing Group All rights reserved 1359-4184/03 $25.00 www.nature.com/mp FEATURE REVIEW Monoamine depletion in psychiatric and healthy populations: review L Booij1, AJW Van der Does1,2 and WJ Riedel3,4,5 1Department of Psychology, Leiden University, Leiden 2333 AK, The Netherlands; 2Department of Psychiatry, Leiden University, Leiden 2333 AK, The Netherlands; 3GlaxoSmithKline, Translational Medicine & Technology, Cambridge, UK; 4Department of Psychiatry, University of Cambridge, UK; 5Faculty of Psychology, Maastricht University, The Netherlands A number of techniques temporarily lower the functioning of monoamines: acute tryptophan depletion (ATD), alpha-methyl-para-tyrosine (AMPT) and acute phenylalanine/tyrosine deple- tion (APTD). This paper reviews the results of monoamine depletion studies in humans for the period 1966 until December 2002. The evidence suggests that all three interventions are specific, in terms of their short-term effects on one or two neurotransmitter systems, rather than on brain protein metabolism in general. The AMPT procedure is somewhat less specific, affecting both the dopamine and norepinephrine systems. The behavioral effects of ATD and AMPT are remarkably similar. Neither procedure has an immediate effect on the symptoms of depressed patients; however, both induce transient depressive symptoms in some remitted depressed patients. The magnitude of the effects, response rate and quality of response are also comparable. APTD has not been studied in recovered major depressive patients. Despite the similarities, the effects are distinctive in that ATD affects a subgroup of recently remitted patients treated with serotonergic medications, whereas AMPT affects recently remitted patients treated with noradrenergic medications.
    [Show full text]
  • The Effects of Clonidine and Idazoxan on Cerebral Blood Flow in Rats Studied by Arterial Spin Labeling Magnetic Resonance Perfusion Imaging
    The Effects of Clonidine and Idazoxan on Cerebral Blood Flow in Rats Studied by Arterial Spin Labeling Magnetic Resonance Perfusion Imaging X. Du1, H. Lei1 1State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, Wuhan Institute of Physics & Mathematics, Chinese Academy of Sciences, Wuhan, Hubei, China, People's Republic of Introduction Agonists of α2-adrenoceptors are known to produce many central and peripheral effects. For example, xylazine, a selective α2-adrenoceptors agonist, has been shown to cause region-dependent CBF decreases in rat [1]. Clonidine, an agonist for both α2-adrenergic receptor and imidazoline receptor, is a widely used drug for treating hypertension. Its effect on CBF, however, is not well understood. In this study, continuous arterial labeling (CASL) MR perfusion imaging was used to investigate the effects of clonidine and idazoxan, an antagonist for α2-adrenergic and imidazoline receptors, on CBF in rats. Materials and Methods Twelve male Sprague-Dawley rats, weighting 250-320 g, were used. After intubation, the rats were anesthetized by 1.0-1.5% isoflurane in a 70:30 N2O/O2 gas mixture. For each rat, bilateral femoral arteries and the right femoral vein were catheterized for monitoring blood gases and blood pressure, and for delivering drugs. Rectal temperature was maintained at 37.0-37.5 oC using a warm water pad. After measuring baseline CBF, the rats were divided into two groups. In the first group (n=7), clonidine (10 µg/kg, i.v.) was injected first, followed by idazoxan injection (300 µg/kg, i.v.) at 30 minutes later. Perfusion maps were obtained after administration of each drug.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Dopamine D2 Receptors in the Cerebral Cortex
    Proc. Nati. Acad. Sci. USA Vol. 86, pp. 6412-6416, August 1989 Neurobiology Dopamine D2 receptors in the cerebral cortex: Distribution and pharmacological characterization with [3Hlraclopride (raclopride binding/neostriatum/rat/monkey) MICHAEL S. LIDOW*t, PATRICIA S. GOLDMAN-RAKIC*, PASKO RAKIC*, AND ROBERT B. INNIS*f Section of *Neuroanatomy and tDepartment of Psychiatry, Yale University, School of Medicine, New Haven, CT 06510 Contributed by Pasko Rakic, May 17, 1989 ABSTRACT An apparent involvement of dopamine in the MATERIALS AND METHODS regulation of cognitive functions and the recognition of a widespread dopaminergic innervation of the cortex have fo- Tissue was obtained from three adult rhesus monkeys cused attention on the identity of cortical dopamine receptors. (Macaca mulatta): one male and two females. The animals However, only the presence and distribution of dopamine DI were anesthesized with sodium pentobarbital (40 mg/kg) and receptors in the cortex have been well documented. Compa- perfused with ice-cold phosphate-buffered saline followed by rable information on cortical D2 sites is lacking. We report here 0.1% paraformaldehyde (9; 15). The cerebral cortex and the results of binding studies in the cortex and neostriatum of neostriatum were rapidly removed and immersed in isopen- rat and monkey using the D2 selective antagonist [3H]raclo- tane at -700C for 5 min before storing at -800C until use. For pride. In both structures [3H]raclopride bound in a sodium- competition studies tissue was pooled from several neocor- dependent and saturable manner to a single population of sites tical areas. However, saturation studies were conducted on with pharmacological profiles of dopamine D2 receptors.
    [Show full text]
  • Psychosis and Schizophrenia in Clinical Practice Psychosis in Practice
    11/1/2017 Psychosis and Schizophrenia in Clinical Practice David Pickar, MD Adjunct Professor Johns Hopkins USUHS Psychosis in Practice • Schizophrenia • Mania • Depression • Brief Psychotic Episodes • Substance Abuse • FASD and other Neurodevelopment Disorders 1 11/1/2017 Schizophrenia • Late Adolescent/Early Adult Age of Onset • Life-Long Condition and Chronic Medication – Typical Antipsychotic drugs – introduced in 50’s -60’s – Atypical Antipsychotic drugs – introduced in later 80’s 90’s – Clozapine is the only ADP with demonstrated superiority – Market For Antipsychotic Drugs : Peak $16B /year US • 1% of World Population • Common “Complex” Disorder – Pathophysiology – Genetics – Variable Phenotype • Positive and Negative Symptoms and Cognitive Deficits • 10% Completed Suicide Prevalence and Treatment Rates • 8.1 million adults with schizophrenia or bipolar disorder mental illness (3.3% of the population)+ • 5.4 million – approximate number with severe bipolar disorder (2.2% of the population), 51% untreated+ • 2.7 million – approximate number with schizophrenia (1.1% of the population), 40% untreated+ • 3.9 million – approximate number untreated seriously mentally ill patients in any given year (1.6% of the population)+ 2 11/1/2017 Positive and Negative Symptom Scale (PANSS) Positive Symptoms • 7 Items, (minimum score = 7, maximum score = 49) • Delusions • Conceptual disorganization • Hallucinations • Excitement • Grandiosity • Suspiciousness/persecution • Hostility 3 11/1/2017 PANSS Negative Symptoms • 7 Items, (minimum score = 7,
    [Show full text]
  • International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors
    1521-0081/67/3/601–655$25.00 http://dx.doi.org/10.1124/pr.114.010249 PHARMACOLOGICAL REVIEWS Pharmacol Rev 67:601–655, July 2015 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ELIOT H. OHLSTEIN International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, and Helmut L. Haas Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry (H.S.) and Institute of Neurophysiology, Medical Faculty (H.L.H.), Heinrich-Heine-University Duesseldorf, Germany; and Janssen Research & Development, LLC, San Diego, California (R.L.T.) Abstract ....................................................................................602 Downloaded from I. Introduction and Historical Perspective .....................................................602 II. Histamine H1 Receptor . ..................................................................604 A. Receptor Structure
    [Show full text]
  • Medication Adherence Failure in Schizophrenia: a Forensic Review of Rates, Reasons, Treatments, and Prospects
    Medication Adherence Failure in Schizophrenia: A Forensic Review of Rates, Reasons, Treatments, and Prospects John L. Young, MD, Reuben T. Spitz, PhD, Marc Hillbrand, PhD, and George Daneri, MSN Forensic patients with schizophrenia who fail to adhere to prescribed antipsy- chotic medication risk recidivism, which continues to be a serious concern. It affects all stages of trial proceedings and impacts on the treaters' liability. Al- though much remains unchanged since the authors reviewed the subject in 1986, significant advances have occurred. A patient's insight can be assessed with greater precision. Risks posed by past noncompliance, substance abuse, and a dysphoric response to medication are more clearly documented. Clinical and laboratory methods for assessing compliance have improved. Major advances in the effective amelioration of adverse effects can be applied to promote adherence. New augmentation strategies enable adequate treatment at lower doses. The development of atypical antipsychotic agents makes compliance easier to achieve and maintain. Other advances apply to the containment of relapse when it does occur. This review organizes the literature documenting these trends for use in both treatment and consultation. Recent advances in the treatment of schizo- with its potential for relapse and recidivism phrenia have so far not improved adherence has not changed over the 12 years since this to treatment nor have they decreased the subject was updated under a forensic codi- public's concern about the violence of some fication.' At the same - time, notable patients with this disorder. In fact, the re- progress in the understanding and treatment ported risk of medication noncompliance of schizophrenia has produced develop- ments hlghly relevant to the problems of The authors are affiliated with the Whiting Forensic Division of Connecticut Valley Hospital, Middletown, noncompliance and relapse.
    [Show full text]
  • Cocaine and Amphetamine Interact at 5HT Synapses Through Distinct Mechanisms in Guinea-Pig Prepositus Hypoglossi
    The Journal of Neuroscience, July 1991, 17(7): 2151-2156 Cocaine and Amphetamine Interact at 5HT Synapses through Distinct Mechanisms in Guinea-pig Prepositus Hypoglossi Daniel H. Bobker and John T. Williams Vellum Institute, Oregon Health Sciences University, Portland, Oregon 97201 Intracellular recordings were made from guinea-pig prepos- two compounds have reinforcing properties in behavioral par- itus hypoglossi (PH) neurons in vitro. Neurons within this adigms (Wise, 1984), and appear to act primarily through mono- nucleus are innervated by terminals that release 5-HT (se- aminergic systems. Cocaine is a potent monoamine uptake in- rotonin) to mediate an IPSP. Cocaine caused a concentra- hibitor (Ross and Renyi, 1967, 1969), and its reinforcing tion-dependent prolongation of that IPSP, while having no properties correlate well with its affinity for the dopamine trans- effect on either membrane potential or firing rate. Cocaine porter (Ritz et al., 1987). Amphetamine is a relatively weaker also caused an increase in the IPSP amplitude at lower con- uptake inhibitor, but it also has monoamine-releasing effects centrations (5 1 PM) and a decrease at higher concentra- and direct agonist actions at some receptors (Homan and Ziance, tions. The selective 5-HT uptake inhibitor fluoxetine also 198 1; Ritz and Kuhar, 1989). The self-administration of am- prolonged the IPSP duration but depressed the amplitude at phetamine and related analogs does not correlate with their all concentrations tested. The effects of cocaine on IPSP affinity for the dopamine transporter, but may correlate nega- duration can be completely accounted for by inhibition of tively with the affinity for the 5-HT transporter (Ritz and Kuhar, 5-HT uptake.
    [Show full text]
  • Supplementary Material a Gene Expression Signature Associated
    Supplementary Material A Gene Expression Signature Associated With Overall Survival in Patients With Hepatocellular Carcinoma Suggests a New Treatment Strategy Jean-Pierre Gillet, Jesper B. Andersen, James P. Madigan, Sudhir Varma, Rachel K. Bagni, Katie Powell, William E. Burgan, Chung-Pu Wu, Anna Maria Calcagno, Suresh V. Ambudkar, Snorri S. Thorgeirsson, Michael M. Gottesman Journal: Molecular Pharmacology Table S1: Compounds highlighted through the Connectivity Map tool Rank for Name of drug on Connectivity Map score - Number of Connectivity Map Probability of getting Proportion of other drugs Drug signature is drug, rated Connectivity Map similarity between the experiments used score normalized an enrichment this that share this same significant for what according to gene expression signature to compute mean using scores from high if there is no signature (smaller values percent of the "n" p-value of drug and the signature similarity random selections of connection between mean that the signature is experiments? used as input genes drug signature and very specific to this input signature particular drug) Rank C-map name Mean n Enrichment p Specificity Percent non-null 1 8-azaguanine 0.916 4 0.975 0 0 100 2 adiphenine -0.765 5 -0.909 0 0.0242 100 3 trichostatin A 0.485 182 0.306 0 0.7204 73 4 tanespimycin 0.474 62 0.297 0 0.3834 72 5 apigenin 0.851 4 0.937 0.00002 0.0234 100 6 0175029-0000 0.797 6 0.86 0.00002 0.0177 100 7 thiamphenicol -0.711 5 -0.903 0.00004 0 100 8 thioguanosine 0.821 4 0.902 0.0001 0.0177 100 9 viomycin -0.723
    [Show full text]
  • Sustained Administration of Pramipexole Modifies the Spontaneous Firing of Dopamine, Norepinephrine, and Serotonin Neurons in the Rat Brain
    Neuropsychopharmacology (2009) 34, 651–661 & 2009 Nature Publishing Group All rights reserved 0893-133X/09 $32.00 www.neuropsychopharmacology.org Sustained Administration of Pramipexole Modifies the Spontaneous Firing of Dopamine, Norepinephrine, and Serotonin Neurons in the Rat Brain ,1 1 1,2 O Chernoloz* , M El Mansari and P Blier 1 2 Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada; Department of Cellular and Molecular Medicine, University of Ottawa, Ontario, Canada Pramipexole (PPX) is a D2/D3 receptor agonist that has been shown to be effective in the treatment of depression. Serotonin (5-HT), norepinephrine (NE) and dopamine (DA) systems are known to be involved in the pathophysiology and treatment of depression. Due to reciprocal interactions between these neuronal systems, drugs selectively targeting one system-specific receptor can indirectly modify the firing activity of neurons that contribute to firing patterns in systems that operate via different neurotransmitters. It was thus hypothesized that PPX would alter the firing rate of DA, NE and 5-HT neurons. To test this hypothesis, electrophysiological experiments were carried out in anesthetized rats. Subcutaneously implanted osmotic minipumps delivered PPX at a dose of 1 mg/kg per day for 2 or 14 days. After a 2-day treatment with PPX the spontaneous neuronal firing of DA neurons was decreased by 40%, NE neuronal firing by 33% and the firing rate of 5-HT neurons remained unaltered. After 14 days of PPX treatment, the firing rate of DA had recovered as well as that of NE, whereas the firing rate of 5-HT neurons was increased by 38%.
    [Show full text]